Versant Capital Management Inc Takes Position in Sanofi (NASDAQ:SNY)

Versant Capital Management Inc bought a new position in shares of Sanofi (NASDAQ:SNY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,116 shares of the company’s stock, valued at approximately $54,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Barrow Hanley Mewhinney & Strauss LLC increased its position in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock valued at $288,381,000 after purchasing an additional 3,164,092 shares during the period. Franklin Resources Inc. raised its position in Sanofi by 13.1% in the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company’s stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in Sanofi by 8.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after acquiring an additional 246,224 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares in the last quarter. Finally, Natixis Advisors LLC grew its stake in shares of Sanofi by 4.1% in the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Stock Performance

Shares of SNY opened at $48.15 on Monday. The company has a 50-day moving average of $49.13 and a two-hundred day moving average of $52.07. The stock has a market cap of $122.20 billion, a price-to-earnings ratio of 24.57, a PEG ratio of 1.23 and a beta of 0.58. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a one year low of $45.22 and a one year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same quarter last year, the business posted $2.55 EPS. The company’s revenue was up 12.3% on a year-over-year basis. On average, equities research analysts expect that Sanofi will post 4.06 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.